HRP20210468T1 - Farmaceutski pripravci koji sadrže dimetil fumarat - Google Patents

Farmaceutski pripravci koji sadrže dimetil fumarat Download PDF

Info

Publication number
HRP20210468T1
HRP20210468T1 HRP20210468TT HRP20210468T HRP20210468T1 HR P20210468 T1 HRP20210468 T1 HR P20210468T1 HR P20210468T T HRP20210468T T HR P20210468TT HR P20210468 T HRP20210468 T HR P20210468T HR P20210468 T1 HRP20210468 T1 HR P20210468T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical preparation
weight
mass
lubricant
magnesium
Prior art date
Application number
HRP20210468TT
Other languages
English (en)
Croatian (hr)
Inventor
Maria PLANELLS JIMENEZ
Begoña Duarte Lopez
Pere Guiro Coll
Original Assignee
Almirall S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49917530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20210468(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall S.A. filed Critical Almirall S.A.
Publication of HRP20210468T1 publication Critical patent/HRP20210468T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20210468TT 2013-12-12 2014-12-05 Farmaceutski pripravci koji sadrže dimetil fumarat HRP20210468T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13382504 2013-12-12
EP14809821.3A EP3079666B1 (en) 2013-12-12 2014-12-05 Pharmaceutical compositions comprising dimethyl fumarate
PCT/EP2014/076767 WO2015086467A1 (en) 2013-12-12 2014-12-05 Pharmaceutical compositions comprising dimethyl fumarate

Publications (1)

Publication Number Publication Date
HRP20210468T1 true HRP20210468T1 (hr) 2021-05-14

Family

ID=49917530

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210468TT HRP20210468T1 (hr) 2013-12-12 2014-12-05 Farmaceutski pripravci koji sadrže dimetil fumarat

Country Status (31)

Country Link
US (2) US20160310457A1 (enExample)
EP (2) EP3079666B1 (enExample)
JP (3) JP6581088B2 (enExample)
KR (2) KR102335289B1 (enExample)
CN (2) CN105813634A (enExample)
AR (1) AR098746A1 (enExample)
AU (2) AU2014363792B2 (enExample)
BR (1) BR112016012179B1 (enExample)
CA (2) CA2932054C (enExample)
CL (1) CL2016001415A1 (enExample)
CY (1) CY1124336T1 (enExample)
DK (1) DK3079666T3 (enExample)
EA (1) EA201600457A1 (enExample)
ES (1) ES2860551T3 (enExample)
HR (1) HRP20210468T1 (enExample)
HU (1) HUE054408T2 (enExample)
IL (2) IL287109B (enExample)
LT (1) LT3079666T (enExample)
MX (2) MX375144B (enExample)
MY (1) MY179355A (enExample)
NZ (2) NZ720287A (enExample)
PH (2) PH12016501043B1 (enExample)
PL (1) PL3079666T3 (enExample)
PT (1) PT3079666T (enExample)
RS (1) RS61658B1 (enExample)
SG (3) SG10201802815UA (enExample)
SI (1) SI3079666T1 (enExample)
SM (1) SMT202100205T1 (enExample)
TW (2) TWI704915B (enExample)
UA (2) UA123880C2 (enExample)
WO (1) WO2015086467A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2713157T3 (es) 2014-02-28 2019-05-20 Banner Life Sciences Llc Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US10085961B2 (en) 2015-06-01 2018-10-02 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
WO2016205754A1 (en) 2015-06-19 2016-12-22 University Of Southern California Compositions and methods for modified nutrient delivery
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
WO2017040272A1 (en) * 2015-08-31 2017-03-09 Banner Life Sciences Llc Fumarate ester dosage forms
WO2017114593A1 (en) * 2015-12-31 2017-07-06 Zaklady Farmaceutyczne Polpharma S.A. Process for preparation of an enteric coated granulate comprising dimethyl fumarate
WO2017129370A1 (en) * 2016-01-28 2017-08-03 Zaklady Farmaceutyczne Polpharma S.A. Process for preparation of a granulate comprising dimethyl fumarate
US20190029987A1 (en) * 2016-02-12 2019-01-31 Universitat Zurich Dimethyl fumarate (dmf) for prevention or treatment of gout, acne, diabetes, vitiligo and/or pyoderma gangrenosum
WO2017145036A1 (en) * 2016-02-25 2017-08-31 Aurobindo Pharma Ltd Pharmaceutical compositions comprising dimethyl fumarate
AU2018287442A1 (en) * 2017-06-23 2019-11-07 Almirall, S.A. Pharmaceutical compositions comprising dimethyl fumarate
JP7000148B2 (ja) * 2017-12-27 2022-01-19 日本化薬株式会社 ダサチニブを有効成分とする医薬組成物
WO2020053219A1 (en) 2018-09-13 2020-03-19 Almirall, S.A. Treatment of psoriasis
WO2020053218A1 (en) 2018-09-13 2020-03-19 Almirall, S.A. Treatment of psoriasis
PH12021552668A1 (en) * 2019-05-31 2022-09-19 Curacle Co Ltd Enteric tablet containing dimethyl fumarate
CA3158394A1 (en) * 2019-11-07 2021-05-14 Asahi Kasei Kabushiki Kaisha Cellulose composition and tablet
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
WO2022203432A1 (ko) * 2021-03-25 2022-09-29 주식회사 큐라클 특정 약동학적 매개변수를 나타내는 디메틸푸마레이트를 유효성분으로 함유한 약학적 조성물
WO2022212893A1 (en) * 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2024232931A1 (en) * 2023-05-11 2024-11-14 Yon Doo Ough Apparatus and method for contact free delivery and administration of magnesium as a drug

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE19848260C2 (de) 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
PL2316430T3 (pl) * 2004-10-08 2012-11-30 Forward Pharma As Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego
JP5149160B2 (ja) * 2005-04-28 2013-02-20 ワイス・エルエルシー ミクロ化タナプロゲットおよびこれを含む組成物
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
WO2007042034A1 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
CN101304732A (zh) * 2005-10-07 2008-11-12 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
WO2009118764A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Pharmaceutical composition comprising diclofenac and paracetamol
WO2010079222A1 (en) 2009-01-09 2010-07-15 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
EP2379062A1 (en) 2009-01-09 2011-10-26 Forward Pharma A/S Pharmaceutical composition comprising one or more fumaric acid esters
EP3318249A1 (en) * 2009-04-29 2018-05-09 Biogen MA Inc. Dimethyl fumarate dosage regimens for the treatment of multiple sclerosis
AR086647A1 (es) * 2011-06-03 2014-01-15 Hoffmann La Roche Metodos para tratar el mesotelioma con un compuesto inhibidor de la pi3k
RU2014125430A (ru) 2011-11-24 2015-12-27 Синтон Бв Контролируемое высвобождение частиц, содержащих диметилфумарат
JP6189333B2 (ja) * 2012-02-07 2017-08-30 バイオジェン エムエー インコーポレーテッド フマル酸ジメチルを含有する医薬組成物

Also Published As

Publication number Publication date
AU2019268075A1 (en) 2019-12-12
CL2016001415A1 (es) 2017-01-20
KR102335289B1 (ko) 2021-12-06
LT3079666T (lt) 2021-03-25
CN114159421B (zh) 2023-08-25
KR20160089397A (ko) 2016-07-27
SG10201802815UA (en) 2018-05-30
TWI687218B (zh) 2020-03-11
AU2014363792B2 (en) 2019-11-14
JP6945603B2 (ja) 2021-10-06
AU2019268075B2 (en) 2020-12-17
CN114159421A (zh) 2022-03-11
PT3079666T (pt) 2021-02-18
CA2932054A1 (en) 2015-06-18
PH12016501043A1 (en) 2016-07-04
SI3079666T1 (sl) 2021-04-30
KR102353201B1 (ko) 2022-01-18
TW201605435A (zh) 2016-02-16
EP3079666B1 (en) 2021-02-03
AR098746A1 (es) 2016-06-08
MX2016007105A (es) 2016-08-11
TWI704915B (zh) 2020-09-21
MX2020009745A (es) 2020-10-08
JP2021130689A (ja) 2021-09-09
CY1124336T1 (el) 2022-07-22
HUE054408T2 (hu) 2021-09-28
SG10201913076PA (en) 2020-02-27
JP2016540003A (ja) 2016-12-22
DK3079666T3 (da) 2021-03-22
UA120428C2 (uk) 2019-12-10
EA201600457A1 (ru) 2016-11-30
AU2014363792A1 (en) 2016-06-09
ES2860551T3 (es) 2021-10-05
US20160310457A1 (en) 2016-10-27
SMT202100205T1 (it) 2021-07-12
TW202011953A (zh) 2020-04-01
MX375144B (es) 2025-03-06
WO2015086467A1 (en) 2015-06-18
CA3135273A1 (en) 2015-06-18
MY179355A (en) 2020-11-05
IL245685A0 (en) 2016-06-30
IL287109A (en) 2021-12-01
CN105813634A (zh) 2016-07-27
NZ720287A (en) 2020-05-29
EP3079666A1 (en) 2016-10-19
BR112016012179A2 (enExample) 2017-08-08
PH12016501043B1 (en) 2016-07-04
BR112016012179B1 (pt) 2023-04-18
CA2932054C (en) 2022-09-20
PH12019502610A1 (en) 2021-02-22
IL245685B (en) 2021-10-31
PL3079666T3 (pl) 2021-09-06
KR20210150587A (ko) 2021-12-10
JP2019218385A (ja) 2019-12-26
UA123880C2 (uk) 2021-06-16
RS61658B1 (sr) 2021-04-29
JP6581088B2 (ja) 2019-09-25
SG10201913080VA (en) 2020-03-30
US20210330628A1 (en) 2021-10-28
IL287109B (en) 2022-08-01
HK1224212A1 (en) 2017-08-18
EP3656379A1 (en) 2020-05-27
NZ759411A (en) 2020-06-26

Similar Documents

Publication Publication Date Title
HRP20210468T1 (hr) Farmaceutski pripravci koji sadrže dimetil fumarat
JP2019218385A5 (enExample)
JP2016540003A5 (enExample)
HRP20240355T1 (hr) 8-cijano-5-piperidino-kinolini kao tlr7/8 antagonisti i njihova upotreba u liječenju imunoloških poremećaja
CL2014003277A1 (es) Compuestos derivados heterociclicos sustituidos por carboxamida o sulfonamida, como moduladores para el receptor nuclear huerfano rorgama; composicion farmaceutica que los comprende, util para el tratamiento de artritis reumatoide, lupus eritematoso, psoriasis, esclerosis multiple, diabetes tipo 1, colitis ulcerosa, enfermedad pulmonar obstructiva cronica, entre otras.
CL2015000945A1 (es) Compuestos derivados de quinolina, como moduladores del receptor nuclear ror-gammat; composicion farmaceutica que los comprende; su proceso de elaboracion, util para el tratamiento de una enfermedad inflamatoria tal como artritis reumatoide, soriasis, epoc, enfermedad de crohn, esclerosis multiple, lupus eritematoso sistemico y colitis ulcerativa.
NZ625087A (en) Combination formulation of two antiviral compounds
CL2015001249A1 (es) Compuestos derivados de piridilo sustituidos con heteroarilo, como moduladores de cinasa; composicion farmaceutica que los comprende; y su uso para el tratamiento de una enfermedad inflamatoria o autoinmunitaria tal como enfermedad de crohn, lupus eritematoso sistemico, esclerosis multiple, gota y artritis gotosa.
BR112015022567A2 (pt) composições compreendendo um opioide e um ingrediente farmacêutico ativo adicional para início rápido e duração prolongada de analgesia que podem ser administradas sem alimento
UY37808A (es) Nuevos compuestos que inhiben la actividad quinasa de la lrrk2
HRP20160203T1 (hr) Pripravci koji sadrže 15-hepe i postupci njihove upotrebe
BR112012021351A2 (pt) composições resistentes à diversão e/ou ao uso abusivo e processos para produção das mesmas
CL2015000615A1 (es) Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau.
BR112017004764A2 (pt) cabo resistente ao fogo, e, composição ceramificável extrusável.
HRP20180967T1 (hr) Pripravak za liječenje hipokalcijemije kod preživača
UY37580A (es) Compuestos novedosos que inhiben la actividad de cinasa lrrk2
CR20140503A (es) Compuestos heterociclicos y sus usos
EP3063258A4 (en) PROCESS FOR PREPARING AN OVERBASED SALT FROM A SULFURIZED, ALKYL SUBSTITUTED AND HYDROXYAROMATIC COMPOSITION
TN2015000356A1 (en) Bicyclic compounds
EP3063115A4 (en) METHOD FOR PRODUCING A PARAVER-BRANCH ALKYL SUBSITUTED HYDROXYAROMATIC COMPOUND
CO2017004504A2 (es) Composición que comprende al menos un polvo seco obtenido por secado por atomización para aumentar la estabilidad de la formulación
BR112017001000A2 (pt) composições de açúcar para preparação de comprimidos por compressão direta
HRP20161611T1 (hr) Uporaba tungsten (vi) soli za liječenje ženske neplodnosti u sisavaca ne-dijabetičara
BR112017008747A2 (pt) composições nutricionais contendo um prebiótico e lactoferrina e seus usos
XIE et al. Value of carbon sink: Concept and evaluation